Can a simple vancomycin taper beat a pricey drug for recurrent c. diff?
NCT ID NCT07328971
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a gradual taper of vancomycin is as good as a 10-day course of fidaxomicin at preventing another C. difficile infection. About 500 adults with a first or second C. diff episode will be randomly assigned to one of the two treatments. The main goal is to see how many people have a repeat infection within 56 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vancomycin and fidaxomicin
What this could lead to
If successful, this could offer a cheaper, simpler way to prevent repeat C. difficile infections, reducing hospital visits and improving quality of life.
What could go wrong
This is a non-inferiority trial, so even if vancomycin works, it may not be better than the current standard. Results may not apply to all patients or settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIA DIFFICILE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
McGill University Health Centre
RECRUITINGMontreal, Quebec, H4A0B1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact